News
Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...
Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback